Zevra Therapeutics, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ZVRA Nasdaq 2834 zevra.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Zevra Therapeutics, Inc.

Zevra Files Definitive Proxy Statement and Mails Letter to Stockholders - Apr 21st, 2025 11:22 am
Zevra Announces Publication of MIPLYFFA® Mechanism of Action Manuscript in Molecular Genetics and Metabolism - Apr 17th, 2025 11:30 am
Zevra Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million - Apr 7th, 2025 11:30 am
Zevra Therapeutics Files Preliminary Proxy - Mar 31st, 2025 8:12 pm
Zevra Therapeutics Independent Director Acquires 33% More Stock - Mar 23rd, 2025 12:34 pm
Zevra Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Mar 13th, 2025 10:20 am
Q4 2024 Zevra Therapeutics Inc Earnings Call - Mar 12th, 2025 4:31 pm
Zevra Therapeutics Inc (ZVRA) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic ... - Mar 12th, 2025 7:06 am
Zevra Therapeutics (ZVRA) Reports Q4 Loss, Tops Revenue Estimates - Mar 11th, 2025 10:15 pm
Zevra Therapeutics: Q4 Earnings Snapshot - Mar 11th, 2025 9:22 pm
Zevra Reports Full Year 2024 and Fourth Quarter Financial Results - Mar 11th, 2025 8:05 pm
Investing in Zevra Therapeutics (NASDAQ:ZVRA) five years ago would have delivered you a 83% gain - Mar 4th, 2025 11:29 am
Zevra Launches New Disease State Awareness Campaign, ‘Learn NPC, Read Between the Signs,’ to Drive Early Recognition and Treatment of Niemann-Pick Disease Type C - Feb 28th, 2025 12:30 pm
Praxis hits trial setback; Bristol Myers lays off staff in New Jersey - Feb 28th, 2025 11:40 am
Zevra sells priority review voucher for $150m to support drug launches - Feb 27th, 2025 11:16 pm
Zevra Therapeutics Enters Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million - Feb 27th, 2025 12:30 pm
Zevra to Report 2024 Fourth Quarter and Full Year Financial Results - Feb 26th, 2025 2:46 pm
Zevra to Participate at Upcoming Investor Conferences - Feb 24th, 2025 9:02 pm
Zevra Therapeutics to Present at the 21st Annual WORLDSymposium™ - Jan 30th, 2025 12:30 pm
Zevra Therapeutics to Participate at Upcoming Investor Conferences - Jan 29th, 2025 9:05 pm